[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Sheldon L. Koenig, President and CEO and Director of Esperion Therapeutics (ESPR), reported a sale and updated holdings. On 09/17/2025 he disposed of 28,427 shares of Esperion common stock at $2.788 per share to satisfy tax obligations on vested restricted stock units. After the reported disposition and recent ESPP purchases, Koenig beneficially owns 1,518,831 shares, which includes 5,770 shares acquired through the company's Employee Stock Purchase Plan. The Form 4 filing is signed 09/18/2025 and reflects that the reporting person is both an officer and a director.

Positive

• Substantial continued ownership: Reporting person beneficially owns 1,518,831 shares after the transaction, indicating ongoing alignment with shareholders.
• Employee participation: The holdings include 5,770 shares recently acquired via the Employee Stock Purchase Plan, showing management participation in company equity programs.

Negative

• Disposition of shares: Sold 28,427 shares on 09/17/2025 at $2.788 per share to satisfy tax obligations, reducing immediate insider holdings.

Insights

Financial Analyst

TL;DR: CEO sold a small block to cover RSU taxes; ownership remains substantial at ~1.52M shares.

The sale of 28,427 shares at $2.788 was disclosed as a tax-related disposition of vested restricted stock units, a common insider liquidity action that is typically non-operational in nature. Koenig retains 1,518,831 shares after the transaction, representing continued alignment with shareholders. The inclusion of 5,770 ESPP shares shows participation in employee equity programs. The trade size relative to total holdings is modest and unlikely to change control or significantly impact market perception absent other disclosures.

Corporate Governance Expert

TL;DR: Insider sale was routine for tax purposes; continued large beneficial ownership supports governance alignment.

The filing identifies Koenig as both President/CEO and a director and documents a disposition to satisfy tax obligations on vested RSUs, which is routinely permitted under company plans. Maintaining over 1.5 million shares suggests persistent economic exposure to company performance, which is generally positive from a governance and alignment perspective. No additional governance actions or unusual transaction codes are reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Koenig Sheldon L.

(Last) (First) (Middle)

C/O ESPERION THERAPEUTICS, INC.

3891 RANCHERO DRIVE, SUITE 150

(Street)

ANN ARBOR MI 48108

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Esperion Therapeutics, Inc. [ ESPR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/17/2025		S		28,427(1)	D	$2.788	1,518,831(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were sold to satisfy tax obligation on vested shares of restricted stock units.

2. Includes 5,770 shares recently acquired in Esperion's Employee Stock Purchase Plan.

Remarks:

	/s/ Sheldon L. Koenig	09/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Esperion (ESPR) insider Sheldon Koenig report on the Form 4?

He reported a sale of 28,427 shares on 09/17/2025 at $2.788 per share and beneficial ownership of 1,518,831 shares following the transaction.

Why were the 28,427 shares sold by the Esperion insider?

The Form 4 states the shares were sold to satisfy tax obligations on vested restricted stock units.

Does the Form 4 indicate Sheldon Koenig's roles at Esperion?

Yes, the filing identifies him as a Director and as an Officer with the title President and CEO.

How many shares were acquired through Esperion's ESPP according to the filing?

The filing notes that 5,770 shares were recently acquired through the Employee Stock Purchase Plan.

When was the Form 4 signed?

The Form 4 was signed by Sheldon L. Koenig on 09/18/2025.